Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Lanadelumab (Synonyms: SHP-643, SHP643, DX-2930, DX2930)

Catalog No. T76710 Copy Product Info
Purity: 95%
🥰Excellent
Lanadelumab (SHP643) is a humanized IgG1 monoclonal antibody targeting plasma kallikrein (pKal) with a Ki value of 0.12 nM. Lanadelumab effectively inhibits both free pKal and its interaction with high molecular weight kininogen (HMWK)-bound pKal. Lanadelumab has demonstrated potential in hereditary angioedema research and represents a promising therapeutic antibody for studying kallikrein-kinin system regulation.

Lanadelumab

Copy Product Info
🥰Excellent
Catalog No. T76710
Synonyms SHP-643, SHP643, DX-2930, DX2930

Lanadelumab (SHP643) is a humanized IgG1 monoclonal antibody targeting plasma kallikrein (pKal) with a Ki value of 0.12 nM. Lanadelumab effectively inhibits both free pKal and its interaction with high molecular weight kininogen (HMWK)-bound pKal. Lanadelumab has demonstrated potential in hereditary angioedema research and represents a promising therapeutic antibody for studying kallikrein-kinin system regulation.

Lanadelumab
Cas No. 1426055-14-2
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$247-In Stock
5 mg$647-In Stock
10 mg$987-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:97.4% (SDS-PAGE); 99.2% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Lanadelumab (SHP643) is a humanized IgG1 monoclonal antibody targeting plasma kallikrein (pKal) with a Ki value of 0.12 nM. Lanadelumab effectively inhibits both free pKal and its interaction with high molecular weight kininogen (HMWK)-bound pKal. Lanadelumab has demonstrated potential in hereditary angioedema research and represents a promising therapeutic antibody for studying kallikrein-kinin system regulation.
Targets&IC50
pKal:0.12 nM (Ki)
In vitro
Lanadelumab (0-1000 nM) inhibits the proteolytic activity of pKal toward its endogenous substrate, single-chain HMWK. Furthermore, in vitro studies demonstrate that Lanadelumab potently prevents HMWK proteolysis and the subsequent release of bradykinin, with an IC50 of 1.3 nM.[2]
In vivo
Lanadelumab (20 mg/kg; i.v. or s.c.) exhibits an extended half-life of approximately 12.5 days and effectively blocks high molecular weight kininogen proteolysis in activated plasma in a dose- and time-dependent manner in cynomolgus monkeys. Additionally, Lanadelumab (1, 30 mg/kg; s.c.) significantly inhibits carrageenan-induced paw edema in male Sprague-Dawley rats.[2]
SynonymsSHP-643, SHP643, DX-2930, DX2930
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetKLKB1/Plasma Kallikrein
Chemical Properties
Molecular Weight145.70 kDa
Cas No.1426055-14-2
Antibody Information
IsotypeHuman IgG1 kappa
Recommended Isotype Control
Storage & Solubility Information
StorageStore at -20°C Shipping with blue ice/Shipping at ambient temperature.

Citations

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Lanadelumab | purchase Lanadelumab | Lanadelumab cost | order Lanadelumab | Lanadelumab in vivo | Lanadelumab in vitro | Lanadelumab molecular weight